BDSI to Present on BEMA(TM) Fentanyl at American Society of Clinical Pharmacology and Therapeutics 2007 Annual Meeting
Dr. Andrew Finn, Executive Vice President of Product Development for BioDelivery Sciences International, Inc. (Nasdaq:BDSI), will present at the American Society of Clinical Pharmacology and Therapeutics 2007 Annual Meeting on Thursday, March 22nd 2007 at the Anaheim Marriott Hotel in Anaheim, California. Beginning at 2:30 PM PDT, Dr. Finn will participate in a panel discussion entitled “Novel routes of drug delivery: eye, cheek, nose and lung” to discuss the potential benefits of buccal drug delivery (between the gum and cheek), highlighting BDSI’s Phase III BEMA™ Fentanyl product for the treatment of breakthrough cancer pain.
BDSI has previously reported that it expects to announce the results of the Phase III efficacy study on BEMA™ Fentanyl for its use in breakthrough cancer pain in April 2007.
To view the slides from Dr. Finn’s presentation, please log on to www.biodeliverysciences.com.
About the BEMA™ Technology
BDSI’s BEMA™ drug delivery technology consists of a dissolvable, dime-sized polymer disc for application to the mucosal (inner lining of cheek) membrane. BEMA™ discs deliver a rapid, reliable dose of drug across mucous membranes for time-critical conditions like “breakthrough” cancer pain (i.e., episodes of severe pain which “break through” the medication used to control the persistent pain), or trauma cases where intravenous lines or injections are neither available nor practical.
About BEMA™ Fentanyl
BDSI’s lead product under development is BEMA™ Fentanyl, a treatment for “breakthrough” cancer pain (i.e., episodes of severe pain which “break through” the medication used to control the persistent pain). BDSI believes there is a clear need and a growing market for additional narcotic agents in alternative dosage forms to provide rapid pain relief. Fentanyl belongs to the group of medicines called narcotic analgesics, which are used to relieve pain. The transmucosal form of Fentanyl is a powerful narcotic used to treat breakthrough cancer pain. BDSI believes that Fentanyl applied with its BEMA™ disc technology has the potential to meet the market need for new narcotics and will be ideal for breakthrough cancer pain in opioid-tolerant patients.
About BioDelivery Sciences International
BioDelivery Sciences International, Inc. is a specialty pharmaceutical company that is focused on developing innovative products to treat acute conditions such as pain. The company utilizes its owned and licensed patented drug delivery technologies to develop, partner and commercialize, clinically-significant new products using proven therapeutics. BDSI’s pain franchise currently consists of two products in development utilizing the company’s patented BEMA™ oral adhesive disc technology: BEMATM Fentanyl, a treatment for “breakthrough” cancer pain, and BEMATM LA, a second analgesic with a target indication of the treatment of moderate to severe pain. The company is also working with both its BEMATM technology and its patented Bioral® nanocochleate technology on products targeted at other acute treatment opportunities such as insomnia, nausea and vomiting, and infections. The company’s headquarters are located in Morrisville, North Carolina and its principal laboratory is located in Newark, New Jersey. For more information please visit www.bdsinternational.com.
Forward-Looking Statements
Note: Except for the historical information contained herein, this press release contains, among other things, certain forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, that involve risks and uncertainties. Such statement may include, without limitation, statements with respect to the Company’s plans, objectives, projections, expectations and intentions and other statements identified by words such as “projects”, “may”, “could”, “would”, “should”, “believes”, “expects”, “anticipates”, “estimates”, “intends”, “plans” or similar expressions. These statements are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties, including those detailed in the Company’s filings with the Securities and Exchange Commission. Actual results, including, without limitation, actual sales results, if any, the application of funds, or the timing for completion and results of scheduled or additional clinical trials and FDA review of the Company’s formulations and products, may differ from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company’s control). Peak sales and market size estimates have been determined on the basis of market research and comparable product analysis, but no assurances can be given that such sales levels will be achieved, if at all.